The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease

BACKGROUND: Synapse damage and loss are fundamental to the pathophysiology of Alzheimer’s disease (AD) and lead to reduced cognitive function. The goal of this review is to address the challenges of forging new clinical development approaches for AD therapeutics that can demonstrate reduction of syn...

Descripción completa

Detalles Bibliográficos
Autores principales: Colom-Cadena, Martí, Spires-Jones, Tara, Zetterberg, Henrik, Blennow, Kaj, Caggiano, Anthony, DeKosky, Steven T., Fillit, Howard, Harrison, John E., Schneider, Lon S., Scheltens, Phillip, de Haan, Willem, Grundman, Michael, van Dyck, Christopher H., Izzo, Nicholas J., Catalano, Susan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053087/
https://www.ncbi.nlm.nih.gov/pubmed/32122400
http://dx.doi.org/10.1186/s13195-020-00588-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053087/
https://www.ncbi.nlm.nih.gov/pubmed/32122400
http://dx.doi.org/10.1186/s13195-020-00588-4

Ejemplares similares